Walmart has opened 70 Specialty Pharmacies of the Community locations across the U.S. in June, and is expected to open 80 more in 11 states by the end of the year.
Taking advantage of new advances in tech-driven engagement to boost patient support and adherence
The key questions and considerations for drug manufacturers pursuing an effective alternative distribution model.
Drugmakers can turn to postponement, or late-stage customization, to help adapt approaches along the supply chain
Exploring new guidances and future challenges for pharma trading partners in meeting looming DSCSA mandates in the US
As a result of the United States Supreme Court’s overturning of Roe v. Wade and Planned Parenthood v. Casey, pharmacy providers are looking to state laws and other recently issued federal guidance in determining how they can compliantly meet patient needs and deliver medications.
The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.
Methods that pharma companies can use to make the hub more personalized and experiential.
New C-Suite position emerges for more emphasis on patient centricity
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
Understanding markets, influencers, and patients through better stakeholder engagement and faster analysis
An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.
An overview of a structural approach that guides development of the analytics and related reporting that may assist brands in gaining or maintaining reimbursement positions and maximizing sales.
Choosing the right pharmacy to administer the program involves a number of factors.
Under the DSCSA law, wholesale distributors, re-packagers, dispensers, and other third-party logistics providers must implement interoperable and electronic tracing of prescription products at the package level.
How can pharma manufacturers and distributors balance logistical demands and environmental impact?
Six steps pharma organizations can follow to help achieve sustainability in their product supply chains
Transitioning a rare disease HUB or NCP program to a rare-focused partner can yield major service quality improvements without program disruption.
How cross-functional commercialization teams can hone their role within clinical management pathways, communicate value to all stakeholders, achieve excellence in evidence generation, and maximize the opportunities of digital technologies
Creating positive experiences and other patient-focused strategies for sponsors to consider when planning and executing cancer studies
How biopharma commercial teams can leverage machine learning techniques to improve targeting of HCPs and patients
Sandra Anderson outlines what manufacturers need to know about the regulatory environment and commercialization solutions for the Canadian market.
Leaders from Janssen, Novartis Gene Therapies, Pierre Fabre, and the German cancer app start-up Mika discuss how they are leveraging data in innovative ways to advance their engagement with the scientific community and their overall commercial operations
Strategies to boost the reproducibility and traceability of cell and gene therapies for more effective clinical studies and commercialization
Exploring RCT, RWE and alternative study designs as a path forward
How digital adoption is driving pharmacovigilance